Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1962 1
1964 1
1967 1
1986 1
1989 1
1990 1
1991 2
1992 5
1993 1
1994 3
1995 7
1996 4
1997 3
1998 2
1999 3
2000 3
2001 6
2002 8
2003 7
2004 15
2005 7
2006 16
2007 12
2008 15
2009 11
2010 11
2011 14
2012 20
2013 12
2014 9
2015 10
2016 8
2017 3
2018 7
2019 7
2020 2
2021 6
2022 9
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Results by year

Filters applied: . Clear all
Page 1
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Quek RGW, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Makharadze T, et al. Among authors: pouliot jf. J Thorac Oncol. 2023 Jun;18(6):755-768. doi: 10.1016/j.jtho.2023.03.008. Epub 2023 Mar 29. J Thorac Oncol. 2023. PMID: 37001859 Free article. Clinical Trial.
Response.
Tidwell WP, Thomas TL, Pouliot JD, Canonico AE, Webber AJ. Tidwell WP, et al. Among authors: pouliot jd. Am J Crit Care. 2019 Mar;28(2):96-97. doi: 10.4037/ajcc2019882. Am J Crit Care. 2019. PMID: 30824509 No abstract available.
Response.
Tidwell WP, Thomas TL, Pouliot JD, Canonico AE, Webber AJ. Tidwell WP, et al. Among authors: pouliot jd. Am J Crit Care. 2019 Mar;28(2):98-99. doi: 10.4037/ajcc2019541. Am J Crit Care. 2019. PMID: 30824511 No abstract available.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M, Kilickap S, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Özgüroğlu M, et al. Among authors: pouliot jf. Lancet Oncol. 2023 Sep;24(9):989-1001. doi: 10.1016/S1470-2045(23)00329-7. Epub 2023 Aug 14. Lancet Oncol. 2023. PMID: 37591293 Clinical Trial.
Response to Letter to the Editor.
Makharadze T, Gogishvili M, Baramidze A, Li S, Li Y, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Makharadze T, et al. Among authors: pouliot jf. J Thorac Oncol. 2023 Jul;18(7):e74-e75. doi: 10.1016/j.jtho.2023.05.012. J Thorac Oncol. 2023. PMID: 37348997 No abstract available.
236 results